Main menu

NEW YORK (GenomeWeb news) – ARUP Laboratories, a diagnostic testing services provider in Salt Lake City, has licensed a biomarker from Epigenomics for use in developing an early detection test for colorectal cancer.

Berlin, Germany-based Epigenomics said today that ARUP has signed a non-exclusive license to use the DNA methylated Septin 9 gene to develop a test for colorectal cancer from a patient's blood sample.

The company said that it has demonstrated that methylated DNA of the Septin 9 gene indicates colorectal cancer in the early stages.